The KAP survey on liver disease, hepatitis B and EPI was conducted in Quang Xuong and Ngoc Lac (Thanh Hoa) in October 2000. The results: there were more than 50% of interviewees giving completely correct answers on liver disease. Monthly visits of EPI staffs increased three times in Ngoc Lac to compare with this of 3 years ago. Radio/TV and loudspeakers are still the main ways to inform EPI activities. Knowledge of mothers on vaccination has been improved. The rate of having birth at CHS has increased in Ngoc Lac (from 6.2% to 34.2%)
Hepatitis, Chronic ; hepatitis B

No abstract available.
Hepatitis B, Chronic* ; Hepatitis, Chronic*

No abstract available.
Hepatitis B, Chronic* ; Hepatitis, Chronic*

No abstract available.
Hepatitis B, Chronic* ; Hepatitis, Chronic*

Hepatitis B, Chronic ; Humans

A study on 56 patients with chronic hepatitis B who were divided into 2 groups: study group and control group. The study group including 31 patients was treated with Thymosin-α1 1.6mg/day, twice a week for 6 months. The control group with 25 patients of same clinical data was treated with common liver-protective drugs. Both groups were monitored and assessed after 24 months. The results showed that the study group with treatment of Thymosin-α1 is better than control one in all aspects of ALT normalization, sero-conversion and decrease of HBV-DNA<5 copies/ml
Hepatitis B, Chronic ; Therapeutics

Hepatitis B, Chronic ; Humans

Study on 60 patients with chronic hepatitis at Infectious diseases department, hospital 103 from February to July 2003. Patients were divided into 2 groups: group 1 included 30 patients who were treated by Atcanninh pack 20g, 3 packs/day; group 2 included 30 patients who were treated by glucose, bile tonic drug, Vitamin B, C. Results: Atcanninh could reduce rapidly some clinical symptoms as fatigue, lose appetite, jaundice, yellow urine. It reduced quickly the blood level of SGOT, SGPT and Bilirubin after 2 to 3 weeks of treatment. Comparing to control group, Atcanninh reduced significantly HBsAg, HBV-DNA concentrations and rate of seroconversion also higher (14.3% compares to 0% with p<0.05) after 3 months
Hepatitis B, Chronic ; Therapeutics

About 5% of the population worldwide (approximately 400 million people) is infected hepatitis B virus (HBV). Over time, 15-40% of chronic HBV-infected people developed cirrhosis. Mortality due to liver failure or other complications of cirrhosis or liver cancer is a global problem. There are about 0.5 million people newly with diagnosed liver cancer annually worldwide, HBV is one of leading causes of liver cancer, especially in the Western Pacific (in which includes Viet Nam). Limitation of HBV infection and treatment of chronic hepatitis B are important for the prevention of cirrhosis and liver cancer in areas with high HBV-infected rate. Comparison with drugs for chronic hepatitis B treatment, telbividine is a novel medicine that was approved recently for clinical trials. The article gave some results of preclinical, phase I/II, IIb, III trials and of study comparing tebivudine with adefovir dipivoxil. The mechanisms of action, pharmacokinetics, side-effects and anti-drug mutations of tebivudine were also mentioned. The author concluded that tebivudine had relatively high possibility of inhibiting replications, had effects for treatment of both positive and negative HBeAg chronic hepatitis B groups.
Chronic hepatitis B ; tebivudine

Background: Hepatitis B infection on pregnancy has been linked to preterm labor, risk of prematurity, low birth weight, and the occurrence of gestational diabetes mellitus. Objective: To determine the association between Chronic Hepatitis B infectivity and fetomaternal outcome such as preterm birth, low birth weight, gestational diabetes and preeclampsia among pregnant patients admitted in a Tertiary Hospital. Methodology: A retrospective cohort study was done among pregnant women diagnosed with chronic hepatitis B infection admitted in a tertiary hospital from January 1, 2014 to December 31, 2018. The association of Hepatitis B infectivity and fetomaternal outcomes namely preterm birth, gestational diabetes, preeclampsia and low birth weight was determined. Results: Chronic Hepatitis B infection had 1.43% prevalence among the study group. 149 patients were able to able to fulfill the inclusion criteria. Pregnant women with high infectivity Hepatitis B infection tend to be younger, have lower BMI, have lesser gravidity and parity than patients who are nonreactive to Hepatitis B e-antigen. AST and ALT were also higher among those with high infectivity Hepatitis B. However, there was no significant difference among the two groups in terms of elevated ALT. There was no significant association between Hepatitis B infectivity and fetomaternal outcomes such as preeclampsia, gestational diabetes mellitus, preterm birth and low birth weight. There is no increased risk for patients with high infectivity for preeclampsia, gestational diabetes mellitus, and low birth weight. There appears to be an excess risk in the likelihood of preterm birth/labor among those women who have a high infectivity Hepatitis B infection during pregnancy. Conclusion The prevalence of chronic hepatitis B infection among Filipino pregnant women admitted in a tertiary hospital was 1.43% from 2014 to 2018. There was no association between chronic hepatitis B infectivity and preeclampsia, Gestational diabetes mellitus. There seems to be an increased risk for HBeAg positive patients for preterm birth preterm labor, and occurrence of low birth weight, but was not statistically significant in the study population.
Hepatitis B, Chronic